Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
Full indication for Cosentyx can be found here
Explore our range of educational resources designed for you and your patients
These promotional resources are designed for healthcare professionals to support their education and the initiation and treatment of patients throughout their Cosentyx journey. Navigate the sections below to find educational resources for download and use by healthcare professionals only, and resources for download and sharing with patients.
Please do not share links to this page with patients; this section of the website is intended for HCP only.
If you do wish to share these with patients, please share this patient portal link www.health.novartis.co.uk/public/medicines/rheumatology/cosentyx/patient-resources
Your guide to flexible dosing with Cosentyx
Download this leaflet which provides information on the recommended dosing regimens for patients with PsA, axSpA, and JIA.
Efficacy with Cosentyx
Download this leaflet which provides an overview of the key efficacy and safety data for Cosentyx across PsA, axSpA, and PsO indications.
Confidence to prescribe Cosentyx
Download this summary of long-term data for Cosentyx which may support you in prescribing with confidence in your eligible patients.
SensoReady® 150 mg injection video
A short video that demonstrates how to prepare and deliver a Cosentyx injection with the SensoReady® pen.
UnoReady® 300 mg injection video
A short video that demonstrates how to prepare and deliver a Cosentyx injection with the UnoReady® pen.
PsA patient leaflet
A useful booklet for PsA patients prescribed Cosentyx to support them in understanding PsA and their treatment journey. It includes instructions on how to administer Cosentyx, the potential side effects, an FAQ to support their well-being and a checklist for travel.
AS patient leaflet
A useful booklet for AS patients prescribed Cosentyx to support them in understanding AS and their treatment journey. It includes instructions on how to administer Cosentyx, the potential side effects, FAQs to support their well-being and a checklist for travel.
ERA patient leaflet
A useful leaflet for parents/caregivers of patients with ERA who have been prescribed Cosentyx. It supports understanding of the disease, how Cosentyx works and how to administer the injections. It also provides support and tips on maintaining well-being.
JPsA patient leaflet
A useful leaflet for parents/caregivers of patients with JPsA who have been prescribed Cosentyx. It supports understanding of the disease, how Cosentyx works and how to administer the injections. It also provides support and tips on maintaining well-being.
UnoReady 300 mg alert leaflet
This short booklet contains information that your patients need to know about the UnoReady® 300 mg injection pen.
Digital dosing schedule
This interactive PDF can be shared with your patients to help them keep track of their Cosentyx treatment.
Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Please refer to the Cosentyx SmPC for full product information and administration, including dosing in special populations, before prescribing.1,2 Cosentyx has not been studied in patients with renal impairment or hepatic impairment. No dose recommendations can be made.
Therapeutic Indications1,2
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active nonradiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1,2
axSpA, axial spondyloarthritis; GB, Great Britain; HCP, healthcare professional; HS, hidradenitis suppurativa; JIA, juvenile idiopathic arthritis; MTX, methotrexate; NI, Northern Ireland; PsA, psoriatic arthritis; PsO, plaque psoriasis; SmPC, Summary of Product Characteristics.
References:
- Cosentyx® (secukinumab) GB Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/3669/smpc [Accessed December 2023].
- Cosentyx® (secukinumab) NI Summary of Product Characteristics. Available at: https://www.emcmedicines.com/en-gb/northernireland/medicine?id=ecdc7f05-... [Accessed December 2023].